Thursday, June 4, 2026 - KFF Health News
• In the phase III INDIGO trial, the investigational monoclonal antibody obexelimab substantially outperformed a placebo in treating immunoglobulin (Ig)G4-related disease. • This development positions obexelimab to compete with the only drug currently approved for the condition, potentially offering patients a new therapeutic option. • Separately, the CDC and state partners published a report in Morbidity and Mortality Weekly Report urging clinicians to increase screening for brucellosis.
kffhealthnews.org

